Immune Therapeutics

Immune Therapeutics is a specialty pharmaceutical company involved in the manufacturing, distribution and marketing of its novel patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system. Company’s technology platform is built on two different immunotherapies, Low Dose Naltrexone (LDN) and Methionine-Enkephalin (MENK).
Type
Public
HQ
Orlando, US
Founded
2012
Size (employees)
10 (est)
Immune Therapeutics was founded in 2012 and is headquartered in Orlando, US

Immune Therapeutics Office Locations

Immune Therapeutics has an office in Orlando
Orlando, US (HQ)
607 37 N Orange Ave
Show all (1)

Immune Therapeutics Financials and Metrics

Immune Therapeutics Financials

Immune Therapeutics's revenue was reported to be $3.5 k in FY, 2016
USD

Net income (Q3, 2017)

(1.6 m)

EBIT (Q3, 2017)

(1.4 m)

Market capitalization (31-Oct-2017)

8.4 m

Closing share price (31-Oct-2017)

0

Cash (30-Sep-2017)

22.6 k
Immune Therapeutics's current market capitalization is $8.4 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

16.2 k3.5 k

Revenue growth, %

(79%)

General and administrative expense

71.1 m4.1 m2.7 m3.9 m

Operating expense total

71.1 m4.1 m2.7 m3.9 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

Revenue

2.1 k5.6 k5 k3.5 k

General and administrative expense

3.7 m901.7 k402 k443.6 k865.3 k939.3 k893.9 k1 m666.1 k620.9 k

Operating expense total

3.7 m901.7 k402 k443.6 k865.3 k939.3 k893.9 k1 m666.1 k1.4 m

Depreciation and amortization

557
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

406.6 k192 k23.1 k74.4 k

Accounts Receivable

16.2 k

Current Assets

622.5 k222 k39.3 k74.4 k

Total Assets

19.2 m6.1 m41.2 k76.4 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

Cash

58.7 k58.6 k30.9 k22.4 k153.9 k132.8 k64.3 k22.2 k98.1 k22.6 k

Accounts Receivable

2.1 k7.7 k12.7 k19.7 k2.7 k

Inventories

214.3 k

Current Assets

93.7 k108.3 k62.9 k60.1 k211.9 k153.4 k78.2 k22.2 k98.1 k236.9 k
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Net Income

    (106.1 m)(49.9 m)(16.9 m)(19.8 m)

    Depreciation and Amortization

    1.2 k2.5 k2.6 k1.6 k

    Accounts Receivable

    (16.2 k)13.5 k

    Inventories

    246.3 k40 k
    USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

    Net Income

    (11.2 m)(2.9 m)(2.6 m)(6.6 m)(2.7 m)

    Accounts Receivable

    2.1 k7.7 k12.7 k19.7 k2.7 k

    Accounts Payable

    1.6 m1.8 m1.9 m1.9 m1.9 m1.9 m1.5 m1.5 m1.7 m
      Show all financial metrics

      Immune Therapeutics Market Value History

      Immune Therapeutics's Web-traffic and Trends

      Immune Therapeutics Online and Social Media Presence

      Immune Therapeutics Company Life and Culture

      You may also be interested in